open access

Vol 92, No 4 (2021)
Research paper
Published online: 2021-03-04
Get Citation

A crosscut survey on reproductive health in Lithuanian childhood cancer survivors

Egle Stukaite-Ruibiene1, Mantas Jurkonis12, Robertas Adomaitis1, Zana Bumbuliene13, Zivile Gudleviciene3, Gilvydas Verkauskas14, Kestutis Zagminas1, Rasa Vaiciuniene2, Jelena Rascon12
DOI: 10.5603/GP.a2021.0027
·
Pubmed: 33757149
·
Ginekol Pol 2021;92(4):262-270.
Affiliations
  1. Vilnius University, Faculty of Medicine, Lithuania
  2. Center for Pediatric Oncology and Hematology, Vilnius University, Lithuania
  3. Center of Obstetrics and Gynecology, Vilnius University, Lithuania
  4. Center of Children’s Surgery, Orthopedics and Traumatology, Vilnius University, Lithuania

open access

Vol 92, No 4 (2021)
ORIGINAL PAPERS Gynecology
Published online: 2021-03-04

Abstract

Objectives: Sexual dysfunction was reported to compromise the quality of life in childhood cancer survivors. The aim of
our study was to evaluate the reproductive health in long-term pediatric cancer survivors by conducting a crosscut survey.
Material and methods: Childhood cancer survivors over 18 years of age, who were in remission for more than 5 years,
were invited to complete a gender-specific questionnaire surveying on their reproductive health. Demographic and treatment
data were retrieved from their medical records. Treatment modalities were reviewed for its potential gonadotoxicity.
Results: 34 (17 males and 17 females, respectively) from 346 addressed survivors (9.8%) completed the questionnaire. Median
age and follow-up after diagnosis was 27 (18–35) and 14 (3–25) years, respectively. Some respondents reported sexual
concerns: 11.8% males experienced problems with penetration, two males (11.8%) who underwent semen analysis were
found to be azoospermic. Similarly, 11.8% females reported delayed puberty, the average age of menarche was 14 (12–17)
years, 29.4% females reported irregular menstrual cycles. Cyclophosphamide equivalent dose (CED) differed significantly
between the patients treated for leukemia, lymphoma and solid tumors (3000 vs 4352 vs 6660 mg/m2, respectively, p = 0.014).
Conclusions: Low prevalence of sexual dysfunction, fertility related disorders or delayed puberty in childhood cancer
survivors was found. However, the results should be interpreted with caution taking into account a low response rate.

Abstract

Objectives: Sexual dysfunction was reported to compromise the quality of life in childhood cancer survivors. The aim of
our study was to evaluate the reproductive health in long-term pediatric cancer survivors by conducting a crosscut survey.
Material and methods: Childhood cancer survivors over 18 years of age, who were in remission for more than 5 years,
were invited to complete a gender-specific questionnaire surveying on their reproductive health. Demographic and treatment
data were retrieved from their medical records. Treatment modalities were reviewed for its potential gonadotoxicity.
Results: 34 (17 males and 17 females, respectively) from 346 addressed survivors (9.8%) completed the questionnaire. Median
age and follow-up after diagnosis was 27 (18–35) and 14 (3–25) years, respectively. Some respondents reported sexual
concerns: 11.8% males experienced problems with penetration, two males (11.8%) who underwent semen analysis were
found to be azoospermic. Similarly, 11.8% females reported delayed puberty, the average age of menarche was 14 (12–17)
years, 29.4% females reported irregular menstrual cycles. Cyclophosphamide equivalent dose (CED) differed significantly
between the patients treated for leukemia, lymphoma and solid tumors (3000 vs 4352 vs 6660 mg/m2, respectively, p = 0.014).
Conclusions: Low prevalence of sexual dysfunction, fertility related disorders or delayed puberty in childhood cancer
survivors was found. However, the results should be interpreted with caution taking into account a low response rate.

Get Citation

Keywords

late effects; long-term survivors; pediatric cancer; reproductive health; sexual dysfunction

Supp./Additional Files (3)
Supplement 1
Download
87KB
Supplement 2
Download
51KB
Supplement 3
Download
79KB
About this article
Title

A crosscut survey on reproductive health in Lithuanian childhood cancer survivors

Journal

Ginekologia Polska

Issue

Vol 92, No 4 (2021)

Article type

Research paper

Pages

262-270

Published online

2021-03-04

DOI

10.5603/GP.a2021.0027

Pubmed

33757149

Bibliographic record

Ginekol Pol 2021;92(4):262-270.

Keywords

late effects
long-term survivors
pediatric cancer
reproductive health
sexual dysfunction

Authors

Egle Stukaite-Ruibiene
Mantas Jurkonis
Robertas Adomaitis
Zana Bumbuliene
Zivile Gudleviciene
Gilvydas Verkauskas
Kestutis Zagminas
Rasa Vaiciuniene
Jelena Rascon

References (50)
  1. Winther JF, Kenborg L, Byrne J, et al. Childhood cancer survivor cohorts in Europe. Acta Oncol. 2015; 54(5): 655–668.
  2. Ness K, Armstrong G, Kundu M, et al. Frailty in childhood cancer survivors. Cancer. 2014; 121(10): 1540–1547.
  3. Zebrack BJ, Foley S, Wittmann D, et al. Sexual functioning in young adult survivors of childhood cancer. Psychooncology. 2010; 19(8): 814–822.
  4. Lee SH, Shin CHo. Reduced male fertility in childhood cancer survivors. Ann Pediatr Endocrinol Metab. 2013; 18(4): 168–172.
  5. Žulpaitė R, Bumbulienė Ž. Reproductive health of female childhood cancer survivors. Ginekol Pol. 2018; 89(5): 280–286.
  6. Kim J, Mersereau JE. A pilot study about female adolescent/young childhood cancer survivors' knowledge about reproductive health and their views about consultation with a fertility specialist. Palliat Support Care. 2015; 13(5): 1251–1260.
  7. Lehmann V, Keim MC, Nahata L, et al. Fertility-related knowledge and reproductive goals in childhood cancer survivors: short communication. Hum Reprod. 2017; 32(11): 2250–2253.
  8. van Dorp W, Haupt R, Anderson RA, et al. Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review. J Clin Oncol. 2018; 36(21): 2169–2180.
  9. Chow EJ, Stratton KL, Leisenring WM, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016; 17(5): 567–576.
  10. Reinmuth S, Hohmann C, Rendtorff R, et al. Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood: the FeCt-survey of childhood cancer survivors in Germany. J Cancer Res Clin Oncol. 2013; 139(12): 2071–2078.
  11. Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001; 91(3): 613–621, doi: 10.1002/1097-0142(20010201)91:3<613::aid-cncr1042>3.0.co;2-r.
  12. Green DM, Nolan VG, Goodman PJ, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014; 61(1): 53–67.
  13. Chemaitilly W, Li Z, Krasin MJ, et al. Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort. J Clin Endocrinol Metab. 2017; 102(7): 2242–2250.
  14. Green DM, Zhu L, Wang M, et al. Effect of cranial irradiation on sperm concentration of adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Study†. Hum Reprod. 2017; 32(6): 1192–1201.
  15. Tutkuviene J. Growth and development criteria for Lithuanian children of various ages. Studies in Human Biology Edited by Bodzsar EB, Susanne C Budapest. ; 1996: 157–64.
  16. Ploug T, Holm S. Meta Consent - A Flexible Solution to the Problem of Secondary Use of Health Data. Bioethics. 2016; 30(9): 721–732.
  17. Gilleland Marchak J, Seidel KD, Mertens AC, et al. Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study. J Cancer Surviv. 2014; 8(3): 437–447.
  18. Yoon JuY, Park HJ, Ju HY, et al. Gonadal and Sexual Dysfunction in Childhood Cancer Survivors. Cancer Res Treat. 2017; 49(4): 1057–1064.
  19. van den Berg MH, Overbeek A, Lambalk CB, et al. DCOG LATER-VEVO study group. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Hum Reprod. 2018; 33(8): 1474–1488.
  20. Ritenour CWM, Seidel KD, Leisenring W, et al. Erectile Dysfunction in Male Survivors of Childhood Cancer-A Report From the Childhood Cancer Survivor Study. J Sex Med. 2016; 13(6): 945–954.
  21. Benedict C, Thom B, Friedman D, et al. Young Adult Female Survivors’ Unmet Information Needs and Reproductive Concerns Contribute to Decisional Conflict about Post-treatment Fertility Preservation. Cancer. 2016; 122(13): 2101–9.
  22. Angarita AM, Johnson CA, Fader AN, et al. Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer. Front Oncol. 2016; 6: 102.
  23. Chapple A, Salinas M, Ziebland S, et al. Fertility issues: the perceptions and experiences of young men recently diagnosed and treated for cancer. J Adolesc Health. 2007; 40(1): 69–75.
  24. Haavisto A, Henriksson M, Heikkinen R, et al. Sexual function in male long-term survivors of childhood acute lymphoblastic leukemia. Cancer. 2016; 122(14): 2268–2276.
  25. Gunn HM, Rinne I, Emilsson H, et al. Primary Gonadal Insufficiency in Male and Female Childhood Cancer Survivors in a Long-Term Follow-Up Clinic. J Adolesc Young Adult Oncol. 2016; 5(4): 344–350.
  26. Haupt R, Essiaf S, Dellacasa C, et al. PanCareSurFup, ENCCA Working Group, ExPo-r-Net Working Group. The 'Survivorship Passport' for childhood cancer survivors. Eur J Cancer. 2018; 102: 69–81.
  27. Matulevicius V, Ostrauskas R, Preikša T, et al. Sexual function of Lithuanian males aged 26–36 years. Sexual Medicine. 2013; 1(1): 7–14.
  28. Yoon JuY, Park HJ, Ju HY, et al. Gonadal and Sexual Dysfunction in Childhood Cancer Survivors. Cancer Res Treat. 2017; 49(4): 1057–1064.
  29. Ritenour CWM, Seidel KD, Leisenring W, et al. Erectile Dysfunction in Male Survivors of Childhood Cancer-A Report From the Childhood Cancer Survivor Study. J Sex Med. 2016; 13(6): 945–954.
  30. Datta J, Palmer MJ, Tanton C, et al. Prevalence of infertility and help seeking among 15 000 women and men. Hum Reprod. 2016; 31(9): 2108–2118.
  31. WHO | Global prevalence of infertility, infecundity and childlessness [updated 2020/03/02/18:30:01]. Available from: https://www who int/reproductivehealth/topics/infertility/burden/en.
  32. Gerstl B, Sullivan E, Koch J, et al. Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2019; 27(12): 4451–4460.
  33. Silva C, Ribeiro Rama AC, Reis Soares S, et al. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments. J Ovarian Res. 2019; 12(1): 102.
  34. La Vignera S, Cannarella R, Duca Y, et al. Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review. Front Endocrinol (Lausanne). 2019; 10: 264.
  35. Huang SM, Tseng LM, Lai JCY, et al. Infertility-related knowledge in childbearing-age women with breast cancer after chemotherapy. Int J Nurs Pract. 2019; 25(5): e12765.
  36. Erenpreiss J, Punab M, Zilaitiene B, et al. Semen quality of young men from the general population in Baltic countries. Hum Reprod. 2017; 32(6): 1334–1340.
  37. Meistrich ML, Wilson G, Brown BW, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer. 1992; 70(11): 2703–2712, doi: 10.1002/1097-0142(19921201)70:11<2703::aid-cncr2820701123>3.0.co;2-x.
  38. Noorda EM, Somers R, Leeuwen FEv, et al. Adult height and age at menarche in childhood cancer survivors. European Journal of Cancer. 2001; 37(5): 605–612.
  39. Mills J, Fears T, Robison L, et al. Menarche in a cohort of 188 long-term survivors of acute lymphoblastic leukemia. The Journal of Pediatrics. 1997; 131(4): 598–602.
  40. Armstrong GT, Whitton JA, Gajjar A, et al. Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer. 2009; 115(11): 2562–2570.
  41. Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013; 14(9): 873–881.
  42. Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006; 98(13): 890–896.
  43. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood. 2008; 111(1): 101–108.
  44. Levine JM, Whitton JA, Ginsberg JP, et al. Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2018; 124(5): 1044–1052.
  45. Thomas-Teinturier C, Allodji RS, Svetlova E, et al. Ovarian reserve after treatment with alkylating agents during childhood. Hum Reprod. 2015; 30(6): 1437–1446.
  46. Elchuri SV, Patterson BC, Brown M, et al. Low Anti-Müllerian Hormone in Pediatric Cancer Survivors in the Early Years after Gonadotoxic Therapy. J Pediatr Adolesc Gynecol. 2016; 29(4): 393–399.
  47. Lie Fo, Laven JSE, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Human Reproduction (Oxford, England. 2009; 24(4): 982–90.
  48. Brougham MFH, Crofton PM, Johnson EJ, et al. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012; 97(6): 2059–2067.
  49. van Dijk EM, van Dulmen-den Broeder E, Kaspers GJL, et al. Psychosexual functioning of childhood cancer survivors. Psychooncology. 2008; 17(5): 506–511.
  50. Langeveld NE, Stam H, Grootenhuis MA, et al. Quality of life in young adult survivors of childhood cancer. Support Care Cancer. 2002; 10(8): 579–600.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl